Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis (ReaSoN-IPF/PPF)
A Prospective, Multicenter, Observational Real-world Study of Nerandomilast Efficacy and Safety in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Nerandomilast is an oral medicine that slows down the loss of functional residual capacity (FVC) in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It was tested in two large clinical trials in which participants were carefully selected. In everyday practice, patients are often older, have more other illnesses, or take additional medicines, and it is not known whether the benefits seen in the trials also occur outside them.
The Real-world Study of Nerandomilast (ReaSoN-IPF/PPF) follows people with IPF or PPF who begin nerandomilast as part of their usual medical care at several medical centers in Israel. The study does not assign any treatment; the treating physician makes every decision about therapy.
The main goal is to find out whether lung function declines more slowly once nerandomilast is started. Because patients have breathing tests before they begin the medicine as well as during treatment, each patient is compared with themselves: the rate at which their FVC was declining beforehand is compared with the rate following treatment.
The study also asks how patients feel, using a questionnaire called the K-BILD, and records side effects, hospital admissions, disease exacerbations, and whether patients stop the medicine.
Participants attend their normal clinic visits. They complete the questionnaire before treatment starts and again at 6 to 12 months, and their routine lung function results are collected. No extra tests or visits are required beyond the questionnaire.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Doron Cohn-Schwartz, MD, PhD
- Número de teléfono: 972-3-6973591
- Correo electrónico: doroncs@tlvmc.gov.il
Copia de seguridad de contactos de estudio
- Nombre: Avraham Unterman, MD, MBA
- Número de teléfono: 972-3-6973591
- Correo electrónico: ramiu@tlvmc.gov.il
Ubicaciones de estudio
-
-
-
Ashkelon, Israel, 7830604
- Reclutamiento
- Barzilai Medical Center, Ben-Gurion University of the Negev
-
Contacto:
- Ori Wand, MD
- Número de teléfono: 972-8-6745465
- Correo electrónico: oriw@bmc.gov.il
-
Haifa, Israel, 3109601
- Reclutamiento
- Rambam Health Care Campus, Technion - Israel Institute of Technology
-
Contacto:
- Yaniv Dotan, MD, PhD
- Número de teléfono: 972-4-8542648
- Correo electrónico: Y_dotan@rmc.gov.il
-
Ramat Gan, Israel, 5265601
- Reclutamiento
- Sheba Medical Center, Tel-HaShomer, Tel-Aviv University
-
Contacto:
- Liran Levy, MD
- Número de teléfono: 972-3-5302745
- Correo electrónico: Liran.Levy@sheba.health.gov.il
-
Tel Aviv, Israel, 6423906
- Reclutamiento
- Tel-Aviv Sourasky University Medical Center, Tel-Aviv University
-
Contacto:
- Doron Cohn-Schwartz, MD, PhD
- Número de teléfono: 972-3-6973591
- Correo electrónico: doroncs@tlvmc.gov.il
-
Contacto:
- Avraham Unterman, MD, MBA
- Número de teléfono: 972-3-6973591
- Correo electrónico: ramiu@tlvmc.gov.il
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Consecutive adults with IPF or PPF followed at one of the participating medical centers who initiate nerandomilast as part of routine clinical care during the enrollment period. Since this is a registry-based study, patients need to be included in a prospective ILD registry in order to participate.
Descripción
Inclusion Criteria:
- Age 18 years or older.
- Physician-confirmed diagnosis of IPF according to current ATS/ERS/JRS/ALAT guidelines, or of PPF (fibrotic interstitial lung disease other than IPF meeting INBUILD criteria for progression).
- Initiating treatment with nerandomilast as part of routine clinical care, with the treatment decision made independently of, and prior to, study enrollment.
- Willing and able to provides written informed consent to participate in the prospective ILD registry of the respective medical center.
Exclusion Criteria:
- Prior exposure to nerandomilast, including in a clinical trial or open-label extension study.
- Concurrent participation in an interventional trial of an investigational agent for interstitial lung disease.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
IPF or PPF
Patients who are diagnosed with IPF |
Either Nerandomilast 9mg twice a day or 18mg twice a day |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse events
Periodo de tiempo: Through study completion, an average of 9 months
|
Proportion of participants experiencing prespecified adverse events (diarrhea, weight loss, nausea, cough, upper respiratory tract infection, dyspnea, nasopharyngitis, worsening of underlying condition, depression, anxiety), reported overall and by severity. |
Through study completion, an average of 9 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Difference between the pre-treatment and on-treatment annualized rate of FVC decline (mL/year)
Periodo de tiempo: Up to 24 months before initiation and, on average, 6 months after initiation
|
Average for all participants. For each participant, the annualized slope of absolute forced vital capacity over the period preceding nerandomilast initiation (derived from at least two pre-treatment measurements obtained within the previous 24 months) is compared with the annualized slope during 12 months of treatment. Each participant serves as their own control; the outcome is the within-participant difference between the two slopes, in mL/year, with a positive value indicating attenuation of decline on treatment. |
Up to 24 months before initiation and, on average, 6 months after initiation
|
|
Difference between pre-treatment and on-treatment annualized rate of FVC decline (% predicted/year)
Periodo de tiempo: Up to 24 months before initiation and, on average, 6 months after initiation
|
As for outcome 2, with FVC expressed as percentage of predicted value. |
Up to 24 months before initiation and, on average, 6 months after initiation
|
|
Difference between pre-treatment and on-treatment annualized rate of DLCO decline (% predicted/year)
Periodo de tiempo: Up to 24 months before initiation and, on average, 6 months after initiation
|
As above, for diffusing capacity of the lungs for carbon monoxide, corrected for hemoglobin. |
Up to 24 months before initiation and, on average, 6 months after initiation
|
|
Change from baseline in K-BILD domain scores
Periodo de tiempo: Baseline and 6-12 months
|
Breathlessness and activities, psychological, and chest symptoms domains, each scored 0-100, higher indicating better health status. |
Baseline and 6-12 months
|
|
Change from baseline in FVC (mL and % predicted)
Periodo de tiempo: Baseline and >6 months
|
Absolute annualized change in forced vital capacity from the pre-treatment baseline measurement. |
Baseline and >6 months
|
|
Change from baseline in DLCO (% predicted)
Periodo de tiempo: Baseline and >6 months
|
Absolute annualized change in hemoglobin-corrected diffusing capacity from the pre-treatment baseline measurement. |
Baseline and >6 months
|
|
Incidence of serious adverse events
Periodo de tiempo: Through study completion, an average of 9 months
|
Proportion of participants with at least one serious adverse event, defined as an event that is fatal, life-threatening, requires or prolongs hospitalization, or results in persistent or clinically significant disability. |
Through study completion, an average of 9 months
|
|
Permanent discontinuation of nerandomilast
Periodo de tiempo: Through study completion, an average of 9 months
|
Proportion of participants permanently discontinuing nerandomilast, time to discontinuation, and reason for discontinuation. |
Through study completion, an average of 9 months
|
|
Dose reduction of nerandomilast
Periodo de tiempo: Through study completion, an average of 9 months
|
Proportion of participants in whom nerandomilast dose is reduced, time to dose reduction, and reason for dose reduction. |
Through study completion, an average of 9 months
|
|
Annualized incidence of acute exacerbation of interstitial lung disease
Periodo de tiempo: Through study completion, an average of 9 months
|
Number and proportion of participants with at least one acute exacerbation, defined according to published criteria, time to exacerbation. |
Through study completion, an average of 9 months
|
|
Annualized incidence of respiratory-cause hospitalization
Periodo de tiempo: Through study completion, an average of 9 months
|
Annualized incidence of respiratory-cause hospitalization |
Through study completion, an average of 9 months
|
|
Annualized all-cause mortality
Periodo de tiempo: Through study completion, an average of 9 months
|
Proportion of participants who die from any cause during follow-up. |
Through study completion, an average of 9 months
|
|
Annualized incidence of lung transplantation
Periodo de tiempo: Through study completion, an average of 9 months
|
Proportion of participants undergoing lung transplantation during follow-up. |
Through study completion, an average of 9 months
|
|
Exploratory: Outcomes stratified by diagnosis, nerandomilast dosage, and background antifibrotic therapy
Periodo de tiempo: Through study completion, an average of 9 months
|
Primary and key secondary outcomes reported separately for IPF versus PPF, and for background nintedanib, pirfenidone, or no background antifibrotic therapy. |
Through study completion, an average of 9 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 0101-21-TLV-A
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .